Literature DB >> 16826345

Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia.

Tatsuya Nakamura1, Hakuo Takahashi.   

Abstract

The purpose of this study was to evaluate the susceptibility to antifungal agents of Candida spp. isolated from blood samples from patients in our hospital, located in Osaka, Japan. We also examined the clinical background of these patients. We analyzed fungi isolated from clinical blood samples obtained in our hospital over a period of 10 years (1993 to 2002). Antifungal susceptibility testing was carried out for six agents, using the National Committee of Clinical Laboratory Standards (NCCLS) M-27-A2 method. The clinical backgrounds were reviewed using the medical records of 125 patients who were diagnosed as having candidemia. The major fungi isolated were Candida parapsilosis (39.2%) and C. albicans (30.1%), and both were sensitive to fluconazole. One strain of C. glabrata and six strains of C. krusei were resistant to fluconazole, and they constituted 4.4% of all Candida spp. isolated. With the exception of C. parapsilosis, most fungi were susceptible to micafungin, although there is no universally agreed breakpoint for this drug. Analysis of the patients' clinical backgrounds revealed that the major underlying disease was cancer (46.4% excluding hematological malignancies). C. krusei was detected almost exclusively in patients with hematological malignancies. Indwelling venous catheters had been responsible for infection in 93.6% of the infected patients. The clinical outcomes of the 125 patients were favorable in 52% and poor in 48%, and subsequent removal of the indwelling catheters was effective in about half of the patients in whom this was done, with good prognosis. To prevent mycosis and its complications, indwelling catheters should be avoided as much as possible. Attention must be paid to the possibility that resistant isolates of Candida spp. can be selected as a result of the use of antifungal agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16826345     DOI: 10.1007/s10156-006-0438-y

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  12 in total

1.  Candidemia distribution, associated risk factors, and attributed mortality at a university-based medical center.

Authors:  Ana Conde-Rosa; Rosana Amador; Doris Pérez-Torres; Eileen Colón; Carlos Sánchez-Rivera; Mariely Nieves-Plaza; Michelle González-Ramos; Jorge Bertrán-Pasarell
Journal:  P R Health Sci J       Date:  2010-03       Impact factor: 0.705

Review 2.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

3.  Association of fluconazole pharmacodynamics with mortality in patients with candidemia.

Authors:  John W Baddley; Mukesh Patel; Sujata M Bhavnani; Stephen A Moser; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

4.  Transcriptional response of Candida parapsilosis following exposure to farnesol.

Authors:  Tristan Rossignol; Mary E Logue; Kieran Reynolds; Muriel Grenon; Noel F Lowndes; Geraldine Butler
Journal:  Antimicrob Agents Chemother       Date:  2007-07       Impact factor: 5.191

5.  Development of a gene knockout system in Candida parapsilosis reveals a conserved role for BCR1 in biofilm formation.

Authors:  Chen Ding; Geraldine Butler
Journal:  Eukaryot Cell       Date:  2007-06-22

6.  Detection of fifteen species of Candida in an automated blood culture system.

Authors:  Lynn L Horvath; Benjamin J George; Duane R Hospenthal
Journal:  J Clin Microbiol       Date:  2007-07-11       Impact factor: 5.948

Review 7.  The effect of biomaterials and antifungals on biofilm formation by Candida species: a review.

Authors:  M Cuéllar-Cruz; A Vega-González; B Mendoza-Novelo; E López-Romero; E Ruiz-Baca; M A Quintanar-Escorza; J C Villagómez-Castro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-12       Impact factor: 3.267

8.  Outcome of Candida Parapsilosis Complex Infections Treated with Caspofungin in Children.

Authors:  İlker Devrim; Rana İşgüder; Hasan Ağın; Gökhan Ceylan; Yüce Ayhan; Özlem Sara Sandal; Ferhat Sarı; Ahu Kara; Mine Düzgöl; Gamze Gülfidan; Nuri Bayram
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-09-01       Impact factor: 2.576

9.  Systemic Candida parapsilosis Infection Model in Immunosuppressed ICR Mice and Assessing the Antifungal Efficiency of Fluconazole.

Authors:  Yu'e Wu; Fangui Min; Jinchun Pan; Jing Wang; Wen Yuan; Yu Zhang; Ren Huang; Lixin Zhang
Journal:  Vet Med Int       Date:  2015-07-09

10.  Conventional and alternative antifungal therapies to oral candidiasis.

Authors:  Paula Cristina Anibal; Janaina de Cássia Orlandi Sardi; Iza Teixeira Alves Peixoto; Julianna Joanna de Carvalho Moraes; José Francisco Höfling
Journal:  Braz J Microbiol       Date:  2010-12-01       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.